📌 Today is Glioblastoma Awareness Day, and we want to take this opportunity to raise awareness about this deadly brain cancer. Glioblastomas are the most common and aggressive type of primary #brain tumor. The symptoms of #glioblastoma can vary depending on the size and location of the #tumor. Common symptoms include headaches, nausea, vomiting, seizures, and problems with thinking, memory, and speech. Glioblastomas are often fatal, with a median survival time of about 15 months. There is no cure for glioblastoma, but there are treatments that can help prolong life and improve the quality of life. Treatment options include surgery, radiation therapy, and chemotherapy. 🧬 #IDH1-2 mutations are found in about 70% of glioblastomas and are important biomarkers for the diagnosis, prognosis, and prediction of response to IDH1-2 inhibitors in patients affected by glioblastoma. Methylation of the #MGMT gene promoter has been observed in approximately 50% of grade IV gliomas. Several studies and clinical trials have definitively established MGMT promoter methylation status as a biomarker in glioma and glioblastoma, predicting the response to alkylating agents such as temozolomide and a powerful prognostic factor. 💊 #PersonalizedMedicine plays a key role in the fight against this terrible disease. We are committed to bringing precision medicine closer to each individual oncology patient by offering innovative, easy-to-use, fast, and standardized testing technologies to any laboratory.  

🎯 Non perdere l’edizione di #ShootingCancerHighlights, la rubrica di informazione periodica sulle approvazioni e le disponibilità di nuove #terapie #oncologiche a bersaglio molecolare. Segui i nostri canali per rimanere aggiornato. 👉 https://lnkd.in/dNJtY3mq 🎯 Don't miss this edition of #ShootingCancerHighlights, the periodic information format focused on approvals and availability of new molecular targeted #therapies in #oncology Follow our channels to stay updated. 👉 https://lnkd.in/dCPkc_8y

📌 Today, on #GISTAwarenessDay, we want to shed light on a rare but impactful disease: Gastrointestinal Stromal Tumor (GIST). #GIST is a type of soft tissue sarcoma that predominantly affects the stomach and small intestine within the digestive system. Although uncommon, its effect on patients and their families is profound and cannot be overlooked. 🔍 Did you know that GIST represents approximately 1% to 3% of all gastrointestinal malignancies? Recent data indicate that around 4,000 to 6,000 new cases are diagnosed worldwide annually. The diagnosis and treatment of GIST are uniquely challenging due to its diverse molecular characteristics and variable clinical manifestations. 🧬 At Diatech Pharmacogenetics, we recognize the critical role of #KIT and #PDGFRA biomarkers in the personalized treatment of GIST. Identifying these #biomarkers enables healthcare professionals to #TtailorTreatment strategies to the individual needs of each patient, enhancing treatment efficacy and improving overall quality of life. 💪 Let’s join forces to foster greater awareness, promote early diagnosis, and advance effective treatments for GIST. Together, we can make a difference in the lives of those affected by this significant disease.

📌 We concluded the second meeting in presence of the Diatech Pharmacogenetics Scientific Board in the beautiful city of Bologna, a place rich in culture and art. It was a fruitful opportunity for exchange and enrichment, where each member generously shared their expertise. The contamination of diverse fields of study and the exceptionally high quality of each presentation provided us with numerous insights to guide our work and projects that will shape the future of our industry. 🌍 After an intense afternoon of work, the Professors were able to marvel at the unique and vast cultural heritage that the city offers. A special thanks to the chairman of the Scientific Board, Stefano Pileri, who guided us by revealing anecdotes and curiosities about his wonderful Bologna See you next year!

📢 Diatech Pharmacogenetics will attend the 36th European Congress of Pathology in Florence from September 7 to 11 🧬 You can find us at booth n. 115! European Society of Pathology #DiatechPharmacogenetics #Pathology

Diatech Pharmacogenetics in qualità di sponsor dell'evento è lieta di invitarvi al "Training Course on Germline and Somatic Pharmacogenetics" il 12-13 settembre 2024 che si terrà a Cagliari. Responsabili Scientifici Monica Miozzo Matteo Floris

🌞 Celebrating Our Summer Company Event! 🌞 We are thrilled to share the amazing moments from our recent summer company event, which brought together all our incredible employees for a day filled with fun, laughter, and team spirit. 🌟 A big thank you to everyone who participated and made this event unforgettable. Here's to many more moments of joy and collaboration! #CompanyEvent #TeamBuilding #SummerFun #CompanyCulture #EmployeeEngagement

👩🔬 Scientific research updates The EGFR mutational analysis was performed by real-time PCR on ctDNA of 118 lung cancer patients using Diatech EasyPGX Ready EGFR. This preliminary study shows that mutational analysis on ctDNA combined with serum tumor marker measurements may represent an integrated strategy for lung cancer monitoring. 👉 “Liquid biopsy and serum tumor markers in lung cancer: a real-life experience.” Arrigo C. et al., Clin Chem Lab Med 2023; 61, Special Suppl, pp S87 – S2222, May 2023. Poster Abstract P2055 – WorldLab • EuroMedLab Roma 2023 👉 Discover more about the EasyPGX ReadyEGFR Line: https://lnkd.in/etarFpCP

Precision oncology is transforming cancer care by tailoring therapies based on individual genetic profiles. Through this cutting-edge approach, we aim to improve outcomes and enhance the quality of life for patients worldwide. 🇧🇷 Join us in our mission to revolutionize cancer treatment! Connect with Mobius our Brazilian partner to learn more about how we are driving the future of precision medicine in oncology. Tommaso Carlini #PrecisionMedicine #Oncology #Pharmacogenetics #HealthcareInnovation #Mobius #DiatechPharmacogenetics #CancerCare